指南与共识肝肾功能剂量调整

基于EMA与FDA指南的经肾小管分泌药物肾脏药物研究设计评估

Evaluation of designs for renal drug studies based on the European Medicines Agency and Food and Drug Administration guidelines for drugs that are predominantly secreted.
指南 / 共识 · Br J Clin Pharmacol · 2020-09-13

该模拟与估计研究评估了EMA和FDA指南推荐的I期肾脏药物研究设计能否区分药物肾清除率与GFR之间的线性与非线性关系。结果显示,EMA设计需≥8例受试者、FDA设计需≥48例受试者才能达到≥80%统计效能;两种设计在参数精度上表现均不佳,FDA设计还存在13-21%的参数估计偏倚。

要点

  • EMA设计区分线性与非线性肾处置所需受试者数(≥8例)少于FDA设计(≥48例)。
  • 两种设计在参数相对标准误上表现均不理想(EMA 13-37%,FDA 17-44%,24例时)。
  • FDA设计存在13-21%的参数估计偏倚,EMA设计未见明显偏倚。

核心结论

  • EMA设计在≥80%效能下区分线性与非线性肾处置所需受试者数(n=8)少于FDA设计(n=48)。
  • 两种设计在参数估计精度上均表现不佳。

研究设计与样本

  • 模拟与估计研究,评估基于EMA和FDA指南的I期肾脏药物研究设计。
  • 每个模拟研究的受试者数范围为4至960例。
  • 计算了统计效能、相对标准误和偏倚。

主要发现

  • EMA和FDA指南设计分别需要≥8例和≥48例受试者才能达到≥80%效能以区分CLR与GFR的线性与非线性关系。
  • 24例受试者时,EMA和FDA设计的参数估计相对标准误分别为13-37%和17-44%。
  • EMA设计的参数估计未见明显偏倚,而FDA设计存在13-21%的偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Dose adjustment for drugs eliminated by the kidneys generally assume a linear relationship between renal drug clearance (CLR ) and glomerular filtration rate (GFR). This assumption may not hold for drugs that undergo extensive tubular secretion where nonlinearity in drug handling is expected. The aim of this study is to determine if renal drug study designs recommended by the European Medicines Agency (EMA) and Food and Drug Administration (FDA) could distinguish linear from nonlinear renal drug handling. METHODS: In this simulation and estimation study, the study designs based on the EMA and FDA guidelines for Phase I renal drug studies were evaluated for their ability to discriminate a linear from a nonlinear relationship between CLR and GFR. The number of subjects for each simulated study ranged from 4 to 960. Power, relative standard error and bias were calculated. RESULTS: Study designs under the EMA and FDA guidelines required ≥8 and ≥48 subjects, respectively, to achieve ≥80% power to discriminate a linear from nonlinear relationship between CLR and GFR. The relative standard error of estimated parameters were 13-37 and 17-44% for the designs with 24 subjects under the EMA and FDA guidelines, respectively. The bias in parameter estimates under the EMA designs were not evident, however, they were biased (13-21%) under the FDA designs. CONCLUSION: The EMA design was found to require fewer subjects (n = 8) compared to the FDA (n = 48) to discriminate linear from nonlinear drug renal handling at ≥80% study power while both the designs perform poorly for the parameter precision.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Pradhan S, Wright DFB, Duffull SB, et al. Evaluation of designs for renal drug studies based on the European Medicines Agency and Food and Drug Administration guidelines for drugs that are predominantly secreted. Br J Clin Pharmacol. 2020. PMID: 32857419. doi:10.1111/bcp.14536

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。